Emerging roles of PGE2 receptors in models of neurological disease

Prostaglandins and Other Lipid Mediators

Volumn 91, Issue 3-4, 2010, Pages 104-112

  Andreasson, Katrin ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease (AD); Amyotrophic lateral sclerosis (ALS); Cerebral ischemia; COX 2; EP1 receptor; EP2 receptor; EP3 receptor; EP4 receptor; Excitotoxicity; Inflammation; Parkinson's disease (PD); PGE2

Indexed keywords

AMYLOID BETA PROTEIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTAGLANDIN E3;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN INJURY; BRAIN ISCHEMIA; CALCIUM TRANSPORT; CATALYSIS; CENTRAL NERVOUS SYSTEM; HUMAN; NERVE DEGENERATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; DISEASE MODEL; METABOLISM;

ANIMALS; DISEASE MODELS, ANIMAL; MODELS, BIOLOGICAL; NERVOUS SYSTEM DISEASES; RECEPTORS, PROSTAGLANDIN E;

EID: 77949540912     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2009.04.003     Document Type: Review

References (155)

1. Yamagata K., Andreasson K.I., Kaufmann W.E., Barnes C.A., and Worley P.F. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 11 2 (1993) 371-386
2. Amateau S.K., and McCarthy M.M. A novel mechanism of dendritic spine plasticity involving estradiol induction of prostaglandin-E2. J Neurosci 22 (2002) 8586-8596
3. Chen C., Magee J.C., and Bazan N.G. Cyclooxygenase-2 regulates prostaglandin E2 signaling in hippocampal long-term synaptic plasticity. J Neurophysiol 87 6 (2002) 2851-2857
4. Miettinen S., Fusco F.R., Yrjanheikki J., et al. Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-d-aspartic acid-receptors and phospholipase A2. Proc Natl Acad Sci USA 94 12 (1997) 6500-6505
5. Adams J., Collaco-Moraes Y., and de Belleroche J. Cyclooxygenase-2 induction in cerebral cortex: an intracellular response to synaptic excitation. J Neurochem 66 1 (1996) 6-13
6. Kaufmann W.E., Andreasson K.I., Isakson P.C., and Worley P.F. Cyclooxygenases and the central nervous system. Prostaglandins 54 (1997) 601-624
7. Takemiya T., Matsumura K., and Yamagata K. Roles of prostaglandin synthesis in excitotoxic brain diseases. Neurochem Int 51 2-4 (2007) 112-120
8. Nogawa S., Zhang F., Ross M.E., and Iadecola C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 17 8 (1997) 2746-2755
9. Nakayama M., Uchimura K., Zhu R.L., et al. Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc Natl Acad Sci USA 95 18 (1998) 10954-10959
10. Dore S., Otsuka T., Mito T., et al. Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction. Ann Neurol 54 2 (2003) 155-162
11. Hoozemans J.J., Rozemuller A.J., Janssen I., De Groot C.J., Veerhuis R., and Eikelenboom P. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol (Berl) 101 1 (2001) 2-8
12. Hoozemans J.J., Veerhuis R., Rozemuller A.J., Arendt T., and Eikelenboom P. Neuronal COX-2 expression and phosphorylation of pRb precede p38 MAPK activation and neurofibrillary changes in AD temporal cortex. Neurobiol Dis 15 3 (2004) 492-499
13. Pasinetti G.M., and Aisen P.S. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 87 2 (1998) 319-324
14. Montine T.J., Sidell K.R., Crews B.C., et al. Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 53 7 (1999) 1495-1498
15. McGeer P.L., and McGeer E.G. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 10 1 (2004) S3-7
16. in t' Veld B.A., Ruitenberg A., Hofman A., et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345 21 (2001) 1515-1521
17. Stewart W.F., Kawas C., Corrada M., and Metter E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48 (1997) 626-632
18. Teismann P., Vila M., Choi D.K., et al. COX-2 and neurodegeneration in Parkinson's disease. Ann NY Acad Sci 991 (2003) 272-277
19. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 63 9 (2004) 901-910
20. Consilvio C., Vincent A.M., Feldman E.L., and Neuroinflammation. COX-2, and ALS-a dual role?. Exp Neurol 187 1 (2004) 1-10
21. Candelario-Jalil E., and Fiebich B.L. Cyclooxygenase inhibition in ischemic brain injury. Curr Pharm Des 14 14 (2008) 1401-1418
22. Yang H., and Chen C. Cyclooxygenase-2 in synaptic signaling. Curr Pharm Des 14 14 (2008) 1443-1451
23. Hewett S.J., Bell S.C., and Hewett J.A. Contributions of cyclooxygenase-2 to neuroplasticity and neuropathology of the central nervous system. Pharmacol Ther 112 2 (2006) 335-357
24. Minghetti L. Role of inflammation in neurodegenerative diseases. Curr Opin Neurol 18 3 (2005) 315-321
25. Bosetti F. Arachidonic acid metabolism in brain physiology and pathology: lessons from genetically altered mouse models. J Neurochem 102 3 (2007) 577-586
26. Breyer R.M., Bagdassarian C.K., Myers S.A., and Breyer M.D. Prostanoid receptors: subtypes and signalling. Annu Rev Pharmacol Toxicol 41 (2001) 661-690
27. Andersohn F., Schade R., Suissa S., and Garbe E. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke; J Cereb Circ 37 7 (2006) 1725-1730
28. Chen L.C., and Ashcroft D.M. Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials. J Clin Pharm Ther 31 6 (2006) 565-576
29. Abraham N.S., El-Serag H.B., Hartman C., Richardson P., and Deswal A. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment Pharmacol Ther 25 8 (2007) 913-924
30. Egan K.M., Lawson J.A., Fries S., et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 306 5703 (2004) 1954-1957
31. Funk C.D., and FitzGerald G.A. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 50 5 (2007) 470-479
32. Rudic R.D., Brinster D., Cheng Y., et al. COX-2-derived prostacyclin modulates vascular remodeling. Circ Res 96 12 (2005) 1240-1247
33. Candelario-Jalil E., Slawik H., Ridelis I., et al. Regional distribution of the prostaglandin E2 receptor EP1 in the rat brain: accumulation in Purkinje cells of the cerebellum. J Mol Neurosci 27 3 (2005) 303-310
34. Kawano T., Anrather J., Zhou P., et al. Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med 12 2 (2006) 225-229
35. Matsuoka Y., Furuyashiki T., Yamada K., et al. Prostaglandin E receptor EP1 controls impulsive behavior under stress. Proc Natl Acad Sci USA 102 44 (2005) 16066-16071
36. Kitaoka S., Furuyashiki T., Nishi A., et al. Prostaglandin E2 acts on EP1 receptor and amplifies both dopamine D1 and D2 receptor signaling in the striatum. J Neurosci 27 47 (2007) 12900-12907
37. McCullough L., Wu L., Haughey N., et al. Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci 24 1 (2004) 257-268
38. Akaike A., Kaneko S., Tamura Y., et al. Prostaglandin E2 protects cultured cortical neurons against N-methyl-d-aspartate receptor-mediated glutamate cytotoxcity. Brain Res 663 (1994) 237-244
39. Cazevieille C., Muller A., Meynier F., Dutrait N., and Bonne C. Protection by prostaglandins from glutamate toxicity in cortical neurons. Neurochem Int 24 4 (1994) 395-398
40. Carlson N.G. Neuroprotection of cultured cortical neurons mediated by the cyclooxygenase-2 inhibitor APHS can be reversed by a prostanoid. J Neurosci Res 71 (2003) 71-88
41. Gendron T.F., Brunette E., Tauskela J.S., and Morley P. The dual role of prostaglandin E(2) in excitotoxicity and preconditioning-induced neuroprotection. Eur J Pharmacol 517 1-2 (2005) 17-27
42. Manabe Y., Anrather J., Kawano T., et al. Prostanoids, not reactive oxygen species, mediate COX-2-dependent neurotoxicity. Ann Neurol 55 5 (2004) 668-675
43. Ahmad A.S., Saleem S., Ahmad M., and Dore S. Prostaglandin EP1 receptor contributes to excitotoxicity and focal ischemic brain damage. Toxicol Sci 89 1 (2006) 265-270
44. Abe T., Kunz A., Shimamura M., Zhou P., Anrather J., and Iadecola C. The neuroprotective effect of prostaglandin E2 EP1 receptor inhibition has a wide therapeutic window, is sustained in time and is not sexually dimorphic. J Cereb Blood Flow Metab 29 1 (2009) 66-72
45. Zhou P., Qian L., Chou T., and Iadecola C. Neuroprotection by PGE2 receptor EP1 inhibition involves the PTEN/AKT pathway. Neurobiol Dis 29 3 (2008) 543-551
46. White E.S., Atrasz R.G., Dickie E.G., et al. Prostaglandin E(2) inhibits fibroblast migration by E-prostanoid 2 receptor-mediated increase in PTEN activity. Am J Respir Cell Mol Biol 32 2 (2005) 135-141
47. Carlson N.G., Rojas M.A., Black J.D., et al. Microglial inhibition of neuroprotection by antagonists of the EP1 prostaglandin E2 receptor. J Neuroinflamm 6 (2009) 5
48. Saleem S., Li R.C., Wei G., and Dore S. Effects of EP1 receptor on cerebral blood flow in the middle cerebral artery occlusion model of stroke in mice. J Neurosci Res 85 11 (2007) 2433-2440
49. Jadhav V., Jabre A., Lin S.Z., and Lee T.J. EP1- and EP3-receptors mediate prostaglandin E2-induced constriction of porcine large cerebral arteries. J Cereb Blood Flow Metab 24 12 (2004) 1305-1316
50. Purdy K.E., and Arendshorst W.J. EP(1) and EP(4) receptors mediate prostaglandin E(2) actions in the microcirculation of rat kidney. Am J Physiol Renal Physiol 279 4 (2000) F755-F764
51. Carrasco E., Casper D., and Werner P. PGE(2) receptor EP1 renders dopaminergic neurons selectively vulnerable to low-level oxidative stress and direct PGE(2) neurotoxicity. J Neurosci Res 85 14 (2007) 3109-3117
52. Carrasco E., Casper D., and Werner P. Dopaminergic neurotoxicity by 6-OHDA and MPP+: differential requirement for neuronal cyclooxygenase activity. J Neurosci Res 81 1 (2005) 121-131
53. Bilak M., Wu L., Wang Q., et al. PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis. Ann Neurol 56 2 (2004) 240-248
54. Zhu P., Genc A., Zhang X., Zhang J., Bazan N.G., and Chen C. Heterogeneous expression and regulation of hippocampal prostaglandin E2 receptors. J Neurosci Res 81 6 (2005) 817-826
55. Amateau S.K., and McCarthy M.M. Induction of PGE2 by estradiol mediates developmental masculinization of sex behavior. Nat Neurosci 7 6 (2004) 643-650
56. Burks S.R., Wright C.L., and McCarthy M.M. Exploration of prostanoid receptor subtype regulating estradiol and prostaglandin E2 induction of spinophilin in developing preoptic area neurons. Neuroscience 146 3 (2007) 1117-1127
57. Ahmadi S., Lippross S., Neuhuber W.L., and Zeilhofer H.U. PGE(2) selectively blocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn neurons. Nat Neurosci 5 1 (2002) 34-40
58. Harvey R.J., Depner U.B., Wassle H., et al. GlyR alpha3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science 304 5672 (2004) 884-887
59. Reinold H., Ahmadi S., Depner U.B., et al. Spinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype. J Clin Invest 115 3 (2005) 673-679
60. Sang N., Zhang J., Marcheselli V., Bazan N.G., and Chen C. Postsynaptically synthesized prostaglandin E2 (PGE2) modulates hippocampal synaptic transmission via a presynaptic PGE2 EP2 receptor. J Neurosci 25 43 (2005) 9858-9870
61. Akaneya Y., and Tsumoto T. Bidirectional trafficking of prostaglandin E2 receptors involved in long-term potentiation in visual cortex. J Neurosci 26 40 (2006) 10209-10221
62. Savonenko A., Munoz P., Melnikova T., et al. Impaired cognition, sensorimotor gating, and hippocampal long-term depression in mice lacking the prostaglandin E2 EP2 receptor. Exp Neurol 217 (2009) 63-73
63. Liu D., Wu L., Breyer R., Mattson M.P., and Andreasson K. Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia. Ann Neurol 57 5 (2005) 758-761
64. Ahmad A.S., Zhuang H., Echeverria V., and Dore S. Stimulation of prostaglandin EP2 receptors prevents NMDA-induced excitotoxicity. J Neurotrauma 23 12 (2006) 1895-1903
65. Carrasco E., Werner P., and Casper D. Prostaglandin receptor EP2 protects dopaminergic neurons against 6-OHDA-mediated low oxidative stress. Neurosci Lett 441 1 (2008) 44-49
66. Li J., Liang X., Wang Q., et al. an anti-ulcer agent and PGE(2) receptor agonist, protects against cerebral ischemia. Neurosci Lett 438 2 (2008) 210-215
67. Kennedy C.R., Zhang Y., Brandon S., et al. Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med 5 2 (1999) 217-220
68. Wu L., Wang Q., Liang X., and Andreasson K. Divergent effects of prostaglandin receptor signaling on neuronal survival. Neurosci Lett 421 3 (2007) 253-258
69. Shie F.S., Montine K.S., Breyer R.M., and Montine T.J. Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity. Glia 52 1 (2005) 70-77
70. Milatovic D., Zaja-Milatovic S., Montine K.S., Shie F.S., and Montine T.J. Neuronal oxidative damage and dendritic degeneration following activation of CD14-dependent innate immune response in vivo. J Neuroinflamm 1 1 (2004) 20
71. Montine T.J., Milatovic D., Gupta R.C., Valyi-Nagy T., Morrow J.D., and Breyer R.M. Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent. J Neurochem 83 2 (2002) 463-470
72. Liang X., Wang Q., Hand T., et al. Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J Neurosci 25 44 (2005) 10180-10187
73. Jin J., Shie F.S., Liu J., et al. Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein. J Neuroinflamm 4 (2007) 2
74. Liang X., Wang Q., Shi J., et al. The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann Neurol 64 3 (2008) 304-314
75. Zhang J., and Rivest S. Distribution, regulation and colocalization of the genes encoding the EP2- and EP4-PGE2 receptors in the rat brain and neuronal responses to systemic inflammation. Eur J Neurosci 11 8 (1999) 2651-2668
76. Akaogi J., Yamada H., Kuroda Y., Nacionales D.C., Reeves W.H., and Satoh M. Prostaglandin E2 receptors EP2 and EP4 are up-regulated in peritoneal macrophages and joints of pristane-treated mice and modulate TNF-alpha and IL-6 production. J Leukoc Biol 76 1 (2004) 227-236
77. Harizi H., Grosset C., and Gualde N. Prostaglandin E2 modulates dendritic cell function via EP2 and EP4 receptor subtypes. J Leukoc Biol 73 6 (2003) 756-763
78. Hubbard N.E., Lee S., Lim D., and Erickson K.L. Differential mRNA expression of prostaglandin receptor subtypes in macrophage activation. Prostagland Leukot Essent Fatty Acids 65 5-6 (2001) 287-294
79. Kubo S., Takahashi H.K., Takei M., et al. E-prostanoid (EP)2/EP4 receptor-dependent maturation of human monocyte-derived dendritic cells and induction of helper T2 polarization. J Pharmacol Exp Ther 309 3 (2004) 1213-1220
80. Fennekohl A., Sugimoto Y., Segi E., Maruyama T., Ichikawa A., and Puschel G.P. Contribution of the two Gs-coupled PGE2-receptors EP2-receptor and EP4-receptor to the inhibition by PGE2 of the LPS-induced TNFalpha-formation in Kupffer cells from EP2-or EP4-receptor-deficient mice. Pivotal role for the EP4-receptor in wild type Kupffer cells. J Hepatol 36 3 (2002) 328-334
81. Vassiliou E., Jing H., and Ganea D. Prostaglandin E2 inhibits TNF production in murine bone marrow-derived dendritic cells. Cell Immunol 223 2 (2003) 120-132
82. Treffkorn L., Scheibe R., Maruyama T., and Dieter P. PGE2 exerts its effect on the LPS-induced release of TNF-alpha, ET-1, IL-1alpha, IL-6 and IL-10 via the EP2 and EP4 receptor in rat liver macrophages. Prostagland Other Lipid Mediat 74 1-4 (2004) 113-123
83. Largo R., Diez-Ortego I., Sanchez-Pernaute O., et al. EP2/EP4 signalling inhibits monocyte chemoattractant protein-1 production induced by interleukin 1beta in synovial fibroblasts. Ann Rheum Dis 63 10 (2004) 1197-1204
84. Noguchi K., Iwasaki K., Shitashige M., et al. Downregulation of lipopolysaccharide-induced intercellular adhesion molecule-1 expression via EP2/EP4 receptors by prostaglandin E2 in human fibroblasts. Inflammation 25 2 (2001) 75-81
85. Timoshenko A.V., Lala P.K., and Chakraborty C. PGE2-mediated upregulation of iNOS in murine breast cancer cells through the activation of EP4 receptors. Int J Cancer 108 3 (2004) 384-389
86. Minghetti L., Nicolini A., Polazzi E., Creminon C., Maclouf J., and Levi G. Inducible nitric oxide synthase expression in activated rat microglial cultures is downregulated by exogenous prostaglandin E2 and by cyclooxygenase inhibitors. Glia 19 (1997) 152-160
87. Fassbender K., Walter S., Kuhl S., et al. The LPS receptor (CD14) links innate immunity with Alzheimer's disease. Faseb J 18 1 (2004) 203-205
88. Hoshino T., Nakaya T., Homan T., et al. Involvement of prostaglandin E2 in production of amyloid-beta peptides both in vitro and in vivo. J Biol Chem 282 45 (2007) 32676-32688
89. Shie F.S., Breyer R.M., and Montine T.J. Microglia lacking E prostanoid receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity. Am J Pathol 166 4 (2005) 1163-1172
90. Aronoff D.M., Canetti C., and Peters-Golden M. Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. J Immunol 173 1 (2004) 559-565
91. Boillee S., Yamanaka K., Lobsiger C.S., et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312 5778 (2006) 1389-1392
92. Di Giorgio F.P., Carrasco M.A., Siao M.C., Maniatis T., and Eggan K. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci 10 5 (2007) 608-614
93. Nagai M., Re D.B., Nagata T., et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 10 5 (2007) 615-622
94. Drachman D.B., Frank K., Dykes-Hoberg M., et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol 52 6 (2002) 771-778
95. Hoffmann A., and Baltimore D. Circuitry of nuclear factor kappaB signalling. Immunol Rev 210 (2006) 171-186
96. Meffert M.K., and Baltimore D. Physiological functions for brain NF-kappaB. Trends Neurosci 28 1 (2005) 37-43
97. Sugimoto Y., and Narumiya S. Prostaglandin E receptors. J Biol Chem 282 16 (2007) 11613-11617
98. Vasilache A.M., Andersson J., and Nilsberth C. Expression of PGE2 EP3 receptor subtypes in the mouse preoptic region. Neurosci Lett 423 3 (2007) 179-183
99. Lazarus M., Yoshida K., Coppari R., et al. EP3 prostaglandin receptors in the median preoptic nucleus are critical for fever responses. Nat Neurosci 10 9 (2007) 1131-1133
100. Ushikubi F., Segi E., Sugimoto Y., et al. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature 395 6699 (1998) 281-284
101. Saleem S., Kim Y.T., Maruyama T., Narumiya S., and Dore S. Reduced acute brain injury in PGE(2) EP3 receptor-deficient mice after cerebral ischemia. J Neuroimmunol 208 1-2 (2009) 87-93
102. Cao J., Shayibuzhati M., Tajima T., Kitazawa T., and Taneike T. In vitro pharmacological characterization of the prostanoid receptor population in the non-pregnant porcine myometrium. Eur J Pharmacol 442 1-2 (2002) 115-123
103. Ahmad M., Ahmad A.S., Zhuang H., Maruyama T., Narumiya S., and Dore S. Stimulation of prostaglandin E2-EP3 receptors exacerbates stroke and excitotoxic injury. J Neuroimmunol 184 1-2 (2007) 172-179
104. Bilson H.A., Mitchell D.L., and Ashby B. Human prostaglandin EP3 receptor isoforms show different agonist-induced internalization patterns. FEBS Lett 572 1-3 (2004) 271-275
105. Hasegawa H., Katoh H., Yamaguchi Y., Nakamura K., Futakawa S., and Negishi M. Different membrane targeting of prostaglandin EP3 receptor isoforms dependent on their carboxy-terminal tail structures. FEBS Lett 473 1 (2000) 76-80
106. Hasegawa H., Negishi M., Katoh H., and Ichikawa A. Two isoforms of prostaglandin EP3 receptor exhibiting constitutive activity and agonist-dependent activity in Rho-mediated stress fiber formation. Biochem Biophys Res Commun 234 3 (1997) 631-636
107. Hasegawa H., Negishi M., and Ichikawa A. Two isoforms of the prostaglandin E receptor EP3 subtype different in agonist-independent constitutive activity. J Biol Chem 271 4 (1996) 1857-1860
108. An S., Yang J., So S.W., Zeng L., and Goetzl E.J. Isoforms of the EP3 subtype of human prostaglandin E2 receptor transduce both intracellular calcium and cAMP signals. Biochemistry 33 48 (1994) 14496-14502
109. Ek M., Arias C., Sawchenko P., and Ericsson-Dahlstrand A. Distribution of the EP3 prostaglandin E(2) receptor subtype in the rat brain: relationship to sites of interleukin-1-induced cellular responsiveness. J Comp Neurol 428 1 (2000) 5-20
110. Nakamura K., Li Y.Q., Kaneko T., Katoh H., and Negishi M. Prostaglandin EP3 receptor protein in serotonin and catecholamine cell groups: a double immunofluorescence study in the rat brain. Neuroscience 103 3 (2001) 763-775
111. Nakamura K., Kaneko T., Yamashita Y., Hasegawa H., Katoh H., and Negishi M. Immunohistochemical localization of prostaglandin EP3 receptor in the rat nervous system. J Comp Neurol 42 (2000) 543-569
112. Nakamura K., Kaneko T., Yamashita Y., et al. Immunocytochemical localization of prostaglandin EP3 receptor in the rat hypothalamus. Neurosci Lett 260 2 (1999) 117-120
113. Waschbisch A., Fiebich B.L., Akundi R.S., et al. Interleukin-1 beta-induced expression of the prostaglandin E-receptor subtype EP3 in U373 astrocytoma cells depends on protein kinase C and nuclear factor-kappaB. J Neurochem 96 3 (2006) 680-693
114. Slawik H., Volk B., Fiebich B., and Hull M. Microglial expression of prostaglandin EP3 receptor in excitotoxic lesions in the rat striatum. Neurochem Int 45 5 (2004) 653-660
115. Hatazawa R., Tanigami M., Izumi N., Kamei K., Tanaka A., and Takeuchi K. Prostaglandin E(2) stimulates VEGF expression in primary rat gastric fibroblasts through EP4 receptors. Inflammopharmacology 15 5 (2007) 214-217
116. Hoshino T., Tsutsumi S., Tomisato W., Hwang H.J., Tsuchiya T., and Mizushima T. Prostaglandin E2 protects gastric mucosal cells from apoptosis via EP2 and EP4 receptor activation. J Biol Chem 278 15 (2003) 12752-12758
117. Jiang G.L., Nieves A., Im W.B., Old D.W., Dinh D.T., and Wheeler L. The prevention of colitis by E Prostanoid receptor 4 agonist through enhancement of epithelium survival and regeneration. J Pharmacol Exp Ther 320 1 (2007) 22-28
118. Xiao C.Y., Yuhki K., Hara A., et al. Prostaglandin E2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4. Circulation 109 20 (2004) 2462-2468
119. Rao R., Redha R., Macias-Perez I., et al. Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo. J Biol Chem 282 23 (2007) 16959-16968
120. Ahmad A.S., Ahmad M., de Brum-Fernandes A.J., and Dore S. Prostaglandin EP4 receptor agonist protects against acute neurotoxicity. Brain Res 1066 1-2 (2005) 71-77
121. Liou J.Y., Ellent D.P., Lee S., et al. Cyclooxygenase-2-derived prostaglandin e2 protects mouse embryonic stem cells from apoptosis. Stem Cells 25 5 (2007) 1096-1103
122. Chun K.S., Akunda J.K., and Langenbach R. Cyclooxygenase-2 inhibits UVB-induced apoptosis in mouse skin by activating the prostaglandin E2 receptors, EP2 and EP4. Cancer Res 67 5 (2007) 2015-2021
123. Sugiura H., Liu X., Togo S., et al. Prostaglandin E(2) protects human lung fibroblasts from cigarette smoke extract-induced apoptosis via EP(2) receptor activation. J Cell Physiol 210 1 (2007) 99-110
124. Tessner T.G., Muhale F., Riehl T.E., Anant S., and Stenson W.F. Prostaglandin E2 reduces radiation-induced epithelial apoptosis through a mechanism involving AKT activation and bax translocation. J Clin Invest 114 11 (2004) 1676-1685
125. Baratelli F., Krysan K., Heuze-Vourc'h N., et al. PGE2 confers survivin-dependent apoptosis resistance in human monocyte-derived dendritic cells. J Leukoc Biol 78 2 (2005) 555-564
126. Sheng H., Shao J., Morrow J.D., Beauchamp R.D., and DuBois R.N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58 2 (1998) 362-366
127. Nishihara H., Kizaka-Kondoh S., Insel P.A., and Eckmann L. Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2. Proc Natl Acad Sci USA 100 15 (2003) 8921-8926
128. Narumiya S., and FitzGerald G.A. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 108 1 (2001) 25-30
129. Zhang Y., Guan Y., Schneider A., Brandon S., Breyer R.M., and Breyer M.D. Characterization of murine vasopressor and vasodepressor prostaglandin E(2) receptors. Hypertension 35 5 (2000) 1129-1134
130. Hristovska A.M., Rasmussen L.E., Hansen P.B., et al. Prostaglandin E2 induces vascular relaxation by E-prostanoid 4 receptor-mediated activation of endothelial nitric oxide synthase. Hypertension 50 3 (2007) 525-530
131. Dumont I., Hou X., Hardy P., et al. Developmental regulation of endothelial nitric oxide synthase in cerebral vessels of newborn pig by prostaglandin E(2). J Pharmacol Exp Ther 291 2 (1999) 627-633
132. Najarian T., Marrache A.M., Dumont I., et al. Prolonged hypercapnia-evoked cerebral hyperemia via K(+) channel- and prostaglandin E(2)-dependent endothelial nitric oxide synthase induction. Circ Res 87 12 (2000) 1149-1156
133. Audoly L.P., Ma L., Feoktistov I., de Foe S.K., Breyer M.D., and Breyer R.M. Prostaglandin E-prostanoid-3 receptor activation of cyclic AMP response element-mediated gene transcription. J Pharmacol Exp Ther 289 1 (1999) 140-148
134. Davis R.J., Murdoch C.E., Ali M., et al. EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries. Br J Pharmacol 141 4 (2004) 580-585
135. Niwa K., Araki E., Morham S.G., Ross M.E., and Iadecola C. Cyclooxygenase-2 contributes to functional hyperemia in whisker-barrel cortex. J Neurosci 20 2 (2000) 763-770
136. Lo E.H., Dalkara T., and Moskowitz M.A. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 4 5 (2003) 399-415
137. Iadecola C. Atherosclerosis and neurodegeneration: unexpected conspirators in Alzheimer's dementia. Arterioscler Thromb Vasc Biol 23 11 (2003) 1951-1953
138. Iadecola C., Zhang F., Niwa K., et al. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci 2 2 (1999) 157-161
139. Park L., Anrather J., Forster C., Kazama K., Carlson G.A., and Iadecola C. Abeta-induced vascular oxidative stress and attenuation of functional hyperemia in mouse somatosensory cortex. J Cereb Blood Flow Metab 24 3 (2004) 334-342
140. Troncoso J.C., Zonderman A.B., Resnick S.M., Crain B., Pletnikova O., and O'Brien R.J. Effect of infarcts on dementia in the Baltimore longitudinal study of aging. Ann Neurol 64 2 (2008) 168-176
141. Schneider J.A., Wilson R.S., Bienias J.L., Evans D.A., and Bennett D.A. Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology 62 7 (2004) 1148-1155
142. Study N.G.M.R.C.C.F.a.A., and Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 357 9251 (2001) 169-175
143. Zhong Z., Deane R., Ali Z., et al. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci 11 4 (2008) 420-422
144. -/- colonic myofibroblasts. Am J Physiol Gastrointest Liver Physiol 292 6 (2007) G1511-G1519
145. Kabashima K., Saji T., Murata T., et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 109 7 (2002) 883-893
146. Nitta M., Hirata I., Toshina K., et al. Expression of the EP4 prostaglandin E2 receptor subtype with rat dextran sodium sulphate colitis: colitis suppression by a selective agonist, ONO-AE1-329. Scand J Immunol 56 1 (2002) 66-75
147. Fushimi K., Nakashima S., You F., Takigawa M., and Shimizu K. Prostaglandin E2 downregulates TNF-alpha-induced production of matrix metalloproteinase-1 in HCS-2/8 chondrocytes by inhibiting Raf-1/MEK/ERK cascade through EP4 prostanoid receptor activation. J Cell Biochem 100 3 (2007) 783-793
148. Minami M., Shimizu K., Okamoto Y., et al. Prostaglandin E receptor type 4-associated protein interacts directly with NF-kappaB1 and attenuates macrophage activation. J Biol Chem 283 15 (2008) 9692-9703
149. Takayama K., Sukhova G.K., Chin M.T., and Libby P. A novel prostaglandin E receptor 4-associated protein participates in antiinflammatory signaling. Circ Res 98 4 (2006) 499-504
150. Takayama K., Garcia-Cardena G., Sukhova G.K., Comander J., Gimbrone Jr. M.A., and Libby P. Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 277 46 (2002) 44147-44154
151. Sakamoto A., Matsumura J., Mii S., Gotoh Y., and Ogawa R. A prostaglandin E2 receptor subtype EP4 agonist attenuates cardiovascular depression in endotoxin shock by inhibiting inflammatory cytokines and nitric oxide production. Shock (Augusta, GA) 22 1 (2004) 76-81
152. Takahashi H.K., Iwagaki H., Tamura R., et al. Differential effect of prostaglandins E1 and E2 on lipopolysaccharide-induced adhesion molecule expression on human monocytes. Eur J Pharmacol 512 2-3 (2005) 223-230
153. Takahashi H.K., Xue D., Iwagaki H., et al. Prostaglandin E1-initiated immune regulation during human mixed lymphocyte reaction. Clin Immunol 115 1 (2005) 85-92
154. Takahashi H.K., Iwagaki H., Tamura R., et al. Unique regulation profile of prostaglandin e1 on adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells. J Pharmacol Exp Ther 307 3 (2003) 1188-1195
155. Takahashi H.K., Iwagaki H., Yoshino T., et al. Prostaglandin E(2) inhibits IL-18-induced ICAM-1 and B7.2 expression through EP2/EP4 receptors in human peripheral blood mononuclear cells. J Immunol 168 9 (2002) 4446-4454